A Phase 2 interventional study of Roflumilast foam 0.3% and Vehicle foam in Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 47 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-10-26.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Psoriasis · Arcutis Biotherapeutics, Inc..
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 7th largest by enrollment, is one of 4 that started in 2020, is one of 5 in phase 2, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →None of the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. is open now. The open studies under Psoriasis, anywhere →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 4
First in 2017; this study’s year is marked. 4 started in 2020.
This study's enrollment of 304 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 318 across the 12 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
This is a parallel group, double blind, vehicle-controlled study in which ARQ-154 foam or vehicle is applied once daily x 8 weeks to adolescent and adult subjects with scalp and body psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
active
Drug: Roflumilast foam 0.3%
placebo
Drug: Vehicle foam
experimental
Also known as: ARQ-154
experimental
Also known as: placebo
Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale
The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.
Time frame: Week 8
Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8
The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.
Time frame: Week 8
Number of Participants Achieving Success in Scalp Itch Numerical Rating Scale (SI-NRS) Score
The number of participants with a baseline SI-NRS score ≥4 who achieve success (a ≥4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.
Time frame: Baseline and Weeks 2, 4, 8
Change From Baseline in Psoriasis Symptoms Diary (PSD) Score
The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.
Time frame: Baseline and Weeks 4 and 8
Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score
The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.
Time frame: Up to 8 weeks
Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75)
The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.
Time frame: Week 8
Number of Participants Achieving PSSI-90
The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.
Time frame: Baseline and Week 8
| Milestone | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Started | 200 | 104 |
| Completed | 177 | 87 |
| Not completed | 23 | 17 |
| Withdrew: Withdrawal by subject | 9 | 6 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 8 | 7 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Not reported | 0 | 2 |
The number of participants achieving success in the S-IGA scale is presented for each arm. Success is defined as an S-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline.The S-IGA is 5-point scale assessing the severity of plaque psoriasis on the scalp, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale | 107 | 10 |
The number of participants achieving success in the B-IGA scale is presented for each arm. Success is defined as a B-IGA score of 0 ('clear') or 1 ('almost clear'), plus a 2-grade improvement from baseline. The B-IGA is 5-point scale assessing the severity of plaque psoriasis on the body, with scores ranging from 0 ('clear') to 4 ('severe'). Higher scores indicate greater symptom severity.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8 | 73 | 6 |
The number of participants with a baseline SI-NRS score ≥4 who achieve success (a ≥4-point improvement from Baseline) at Weeks 2, 4, and 8 is presented for each arm. The SI-NRS is a participant-reported rating of severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ('no itch') to 10 ('worst imaginable itch'), with higher scores indicating greater symptom severity. Results are based on observed data only.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 2 | 74 | 14 |
| Week 4 | 98 | 19 |
| Week 8 | 110 | 15 |
The change from baseline in total PSD scores at Weeks 4 and 8 is presented for each arm. The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity.
| score on a scale | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Week 4 | -45.0 (-53.8 to -36.1) | -25.4 (-35.2 to -15.6) |
| Week 8 | -55.0 (-64.0 to -46.1) | -27.5 (-37.5 to -17.6) |
The time to achieve PSSI-50 (i.e., a 50% reduction from baseline in PSSI score) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicating greater symptom severity. Results are based on observed data only.
| days | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Time to Achieve a 50% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI-50) Score | 28.0 (17.0 to 29.0) | NA (67 to NA) |
The number of participants achieving a 75% reduction in PSSI score (i.e., PSSI-75) from baseline. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Number of Participants Achieving Psoriasis Scalp Severity Index-75 (PSSI-75) | 121 | 19 |
The number of participants achieving a 90% reduction from baseline PSSI score (i.e., PSSI-90) is presented for each arm. The PSSI measures the extent of psoriasis involvement and the severity of erythema, induration, and desquamation of the scalp. Involvement and severity of psoriasis for the PSSI is scored using a scale of 0 to 72, where 0 = no psoriasis and higher scores indicate greater symptom severity. Results are based on observed data only.
| Participants | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Number of Participants Achieving PSSI-90 | 84 | 3 |
Collected over Up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast Foam 0.3% | 0/198 (0%) | 1/198 (0.5%) | 0/198 (0%) |
| Vehicle Foam | 0/104 (0%) | 0/104 (0%) | 0/104 (0%) |
| Event | Roflumilast Foam 0.3% | Vehicle Foam |
|---|---|---|
| Testicular torsionReproductive system and breast disorders | 1/198 | 0/104 |
| Age, Continuous(years) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 45.2 ± 14.22 | 45.0 ± 15.76 | 45.1 ± 14.74 |
| Sex: Female, Male(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Female | 96 | 47 | 143 |
| Male | 104 | 57 | 161 |
| Ethnicity (NIH/OMB)(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 25 | 63 |
| Not Hispanic or Latino | 161 | 79 | 240 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 9 | 6 | 15 |
| White | 180 | 91 | 271 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Scalp Investigator Global Assessment (S-IGA) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 0 - clear | 0 | 0 | 0 |
| 1 - almost clear | 0 | 0 | 0 |
| 2 - mild | 18 | 14 | 32 |
| 3 - moderate | 151 | 80 | 231 |
| 4 - severe | 29 | 10 | 39 |
| Psoriasis Scalp Severity Index (PSSI) Baseline Score(score on a scale) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 22.4 ± 12.52 | 20.9 ± 11.70 | 21.9 ± 12.25 |
| Body Investigator Global Assessment (B-IGA) Baseline Score(Participants) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| 0 - clear | 0 | 0 | 0 |
| 1 - almost clear | 0 | 0 | 0 |
| 2 - mild | 69 | 39 | 108 |
| 3 - moderate | 119 | 60 | 179 |
| 4 - severe | 10 | 5 | 15 |
| Scalp Itch Numeric Rating Scale (SI-NRS) Baseline Score(score on a scale) | Roflumilast Foam 0.3% | Vehicle Foam | Total |
|---|---|---|---|
| Mean | 6.4 ± 2.35 | 6.6 ± 2.25 | 6.5 ± 2.31 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Sep 2020, 8 months.
Results were first posted in Sep 2022, 2 years after primary completion. A results delay was requested in Jun 2021.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 8 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ARQ-154
Arcutis Biotherapeutics, Inc. →